

BREAST

AFT-05 (PALLAS) PALbociclib CoLLaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

<https://clinicaltrials.gov/ct2/show/NCT02513394?term=aft-05&rank=1>

NSABP B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.

<https://clinicaltrials.gov/ct2/show/NCT01872975?term=b51&rank=1>

A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy.

<https://clinicaltrials.gov/ct2/show/NCT01901094?term=A011202&rank=1>

SWOG S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer.

<https://clinicaltrials.gov/ct2/show/NCT01674140?term=S1207&rank=1>

WO29479: A multistage, phase II study evaluating the safety and efficacy of Cobimetinib (MAPK inhibitor) in combination with paclitaxel as first-line treatment for patients with metastatic triple-negative breast Cancer- Colet.

<https://clinicaltrials.gov/ct2/show/NCT02322814?term=WO29479&rank=1>

3000-PN162-01-001: Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer (Phase 2)

<https://clinicaltrials.gov/ct2/show/NCT02657889?term=3000-PN162-01-001&rank=1>



PENDING NEW STUDIES

ALLIANCE FH IRB AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

<https://clinicaltrials.gov/ct2/show/NCT02947685?term=AFT-38&rank=1>

